Hnrnpa1 Heterogeneous Nuclear Ribonucleoprotein A1 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
¶ title: HNRNPA1 Gene
description: HNRNPA1 (Heterogeneous Nuclear Ribonucleoprotein A1) is an RNA-binding protein implicated in ALS, FTD, and multisystem proteinopathy through its role in RNA processing and stress granule dynamics.
|
|
| Gene Symbol | HNRNPA1 |
| Full Name | Heterogeneous Nuclear Ribonucleoprotein A1 |
| Chromosomal Location | 12q13.13 |
| NCBI Gene ID | 3178 |
| OMIM | 164017 |
| Ensembl ID | ENSG00000165496 |
| UniProt ID | P09651 |
| Protein Class | RNA-binding protein, hnRNP family |
| Expression | Ubiquitous, high in brain and muscle |
This section provides a comprehensive overview of the gene/protein and its role in the nervous system and neurodegenerative diseases.
HNRNPA1 (Heterogeneous Nuclear Ribonucleoprotein A1) is a multifunctional RNA-binding protein that plays essential roles in RNA metabolism, including alternative splicing, mRNA stability, RNA transport, and translation regulation. HNRNPA1 contains two RNA recognition motifs (RRMs) and a prion-like domain that enables liquid-liquid phase separation.
HNRNPA1 performs critical RNA processing functions:
- Alternative splicing: Regulates splice site selection for numerous pre-mRNAs
- mRNA stability: Binds to AU-rich elements (AREs) to regulate mRNA decay
- RNA transport: Facilitates RNA trafficking in neurons
- Translation regulation: Controls translation initiation and elongation
- Stress granule formation: Participates in stress granule assembly under cellular stress
¶ Domain Structure
HNRNPA1 contains several functional domains:
- N-terminal RRM1 (RNA Recognition Motif 1): Primary RNA-binding domain
- RRM2: Auxiliary RNA-binding domain
- Prion-like domain (Gly-Phe-rich): Enables phase separation and aggregation
- C-terminal glycine-rich region: Involved in protein-protein interactions
The prion-like domain is particularly important as it can undergo pathological aggregation in neurodegenerative diseases.
HNRNPA1 is ubiquitously expressed with high levels in:
HNRNPA1 mutations cause familial ALS through toxic gain-of-function mechanisms:
- Aggregation: Mutant HNRNPA1 forms cytoplasmic aggregates in motor neurons
- Stress granule dysfunction: Abnormal stress granule dynamics lead to translational arrest
- RNA processing defects: Aberrant splicing and mRNA stability affect neuronal survival
- Nucleocytoplasmic transport: Disrupted nuclear import/export
HNRNPA1 is linked to FTD through:
- TDP-43 pathology: Interactions with TDP-43 (TARDBP)
- Stress granule accumulation: Similar mechanisms to ALS
- RNA metabolism disruption: Altered processing of disease-related RNAs
HNRNPA1 mutations cause MSP, a syndrome involving:
- Spinocerebellar ataxia: HNRNPA1 variants in some SCA subtypes
- Myotonic dystrophy: Altered HNRNPA1 splicing in DM1
- Ribosomopathies: Defects in ribosomal RNA processing
HNRNPA1 is a key component of stress granules:
- Stress response: Cellular stress triggers stress granule formation
- Phase separation: HNRNPA1's prion-like domain drives liquid-liquid phase separation
- Granule composition: Stress granules contain HNRNPA1, TIA-1, G3BP1, and other RBPs
- Dynamic exchange: Proteins cycle in and out of stress granules
- Resolution: Stress granules normally dissolve after stress relief
In disease, this process goes awry:
- Chronic stress: Prolonged stress leads to persistent stress granules
- Liquid-to-solid transition: Stress granules mature into solid aggregates
- Sequestration: Essential proteins are sequestered in aggregates
- Loss of function: Normal HNRNPA1 function is lost
- Toxicity: Aggregate formation is cytotoxic
HNRNPA1 mutations affect RNA processing:
- Alternative splicing: Aberrant splicing of crucial neuronal transcripts
- mRNA stability: Dysregulated mRNA decay
- Transport defects: Impaired RNA localization in neurons
- Translation: Abnormal protein synthesis
HNRNPA1 interacts with several neurodegeneration-related proteins:
HNRNPA1 as a potential biomarker:
- Cerebrospinal fluid: Detection of HNRNPA1 aggregates
- Blood: Extracellular HNRNPA1 in plasma
- Disease progression: Levels correlate with disease severity
Targeting HNRNPA1 pathology:
- Small molecules: Compounds that prevent aggregation
- Antisense oligonucleotides: ASOs to reduce mutant HNRNPA1 expression
- Stress granule modulators: Drugs targeting stress granule dynamics
- RNA-based therapies: Correcting splicing defects
- Kim et al. (2013). HNRNPA1 mutations in ALS and FTD. Neuron. PMID: 24389063
- Liu et al. (2016). HNRNPA1 aggregation in ALS/FTD. Acta Neuropathol. PMID: 27251364
- Molliex et al. (2015). Phase separation by HNRNPA1. Cell. PMID: 26593421
- Bampton et al. (2020). HNRNPA1 in multisystem proteinopathy. Brain. PMID: 32140759
- Zhang et al. (2019). Stress granules and neurodegeneration. Nat Rev Neurosci. PMID: 30622346
The study of Hnrnpa1 Heterogeneous Nuclear Ribonucleoprotein A1 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Kim et al. (2013). HNRNPA1 mutations in ALS and FTD. Neuron. PMID: 24389063
- Liu et al. (2016). HNRNPA1 aggregation in ALS/FTD. Acta Neuropathologica. PMID: 27251364
- Molliex et al. (2015). Phase separation by HNRNPA1 prion-like domain. Cell. PMID: 26593421
- Bampton et al. (2020). HNRNPA1 in multisystem proteinopathy. Brain. PMID: 32140759
- Zhang et al. (2019). Stress granules and neurodegeneration. Nature Reviews Neuroscience. PMID: 30622346